Literature DB >> 21732763

Free-radical scavenger edaravone treatment confers neuroprotection against traumatic brain injury in rats.

Guo-Hua Wang1, Zheng-Lin Jiang, Yong-Cai Li, Xia Li, Hong Shi, Yan-Qin Gao, Peter S Vosler, Jun Chen.   

Abstract

Traumatic brain injury (TBI) is one of the leading causes of neurological disability in young adults. Edaravone, a novel synthetic small-molecule free-radical scavenger, has been shown to have a neuroprotective effect in both animal models of cerebral ischemia and stroke patients; however, the underlying mechanism is poorly understood. In this report, we investigated the potential mechanisms of edaravone treatment in a rat model of TBI. TBI was induced in the right cerebral cortex of male adult rats using Feeney's weight-drop method. Edaravone (0.75, 1.5, or 3 mg/kg) or vehicle (normal saline) was intravenously administered at 2 and 12 h after TBI. Edaravone treatment significantly decreased hippocampal CA3 neuron loss, reduced oxidative stress, and decreased neuronal programmed cell death compared to vehicle treatment. The protective effects of edaravone treatment were also related to the pathology of TBI on non-neuronal cells, as edaravone decreased astrocyte and glial activation. Lastly, edaravone treatment significantly reduced the presence of inflammatory cytokines, cerebral edema, blood-brain barrier (BBB) permeability, and, importantly, neurological deficits following TBI. Our results suggest that edaravone exerts a neuroprotective effect in the rat model of TBI. The likely mechanism is via inhibiting oxidative stress, leading to a decreased inflammatory response and glial activation, and thereby reducing neuronal death and improving neurological function.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21732763      PMCID: PMC3191368          DOI: 10.1089/neu.2011.1939

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  46 in total

1.  Edaravone: a new therapeutic approach for the treatment of acute stroke.

Authors:  Kiyoshi Kikuchi; Ko-ichi Kawahara; Naohisa Miyagi; Hisaaki Uchikado; Terukazu Kuramoto; Yoko Morimoto; Salunya Tancharoen; Naoki Miura; Kazunori Takenouchi; Yoko Oyama; Binita Shrestha; Fumiyo Matsuda; Yoshihiro Yoshida; Shinichiro Arimura; Kentaro Mera; Ko-ichi Tada; Narimasa Yoshinaga; Ryuichi Maenosono; Yoshiko Ohno; Teruto Hashiguchi; Ikuro Maruyama; Minoru Shigemori
Journal:  Med Hypotheses       Date:  2010-08-21       Impact factor: 1.538

Review 2.  Pharmacological management of neurobehavioral disorders following traumatic brain injury--a state-of-the-art review.

Authors:  Effie Chew; Ross D Zafonte
Journal:  J Rehabil Res Dev       Date:  2009

Review 3.  Antioxidant therapies for traumatic brain injury.

Authors:  Edward D Hall; Radhika A Vaishnav; Ayman G Mustafa
Journal:  Neurotherapeutics       Date:  2010-01       Impact factor: 7.620

Review 4.  Oxidative stress following traumatic brain injury: enhancement of endogenous antioxidant defense systems and the promise of improved outcome.

Authors:  P O Eghwrudjakpor; A B Allison
Journal:  Niger J Med       Date:  2010 Jan-Mar

Review 5.  Advances in methods for the determination of biologically relevant lipid peroxidation products.

Authors:  Corinne M Spickett; Ingrid Wiswedel; Werner Siems; Kamelija Zarkovic; Neven Zarkovic
Journal:  Free Radic Res       Date:  2010-10

6.  Neuroprotective effects of hyperbaric oxygen treatment on traumatic brain injury in the rat.

Authors:  Guo-Hua Wang; Xiang-Gen Zhang; Zheng-Lin Jiang; Xia Li; Liang-Liang Peng; Yong-Cai Li; Yong Wang
Journal:  J Neurotrauma       Date:  2010-09       Impact factor: 5.269

Review 7.  Blood-brain barrier breakdown as a therapeutic target in traumatic brain injury.

Authors:  Dan Shlosberg; Mony Benifla; Daniela Kaufer; Alon Friedman
Journal:  Nat Rev Neurol       Date:  2010-06-15       Impact factor: 42.937

Review 8.  A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy?

Authors:  Paul A Lapchak
Journal:  Expert Opin Pharmacother       Date:  2010-07       Impact factor: 3.889

Review 9.  Cell death mechanisms and modulation in traumatic brain injury.

Authors:  Bogdan A Stoica; Alan I Faden
Journal:  Neurotherapeutics       Date:  2010-01       Impact factor: 7.620

10.  Effects of edaravone on muscle atrophy and locomotor function in patients with ischemic stroke: a randomized controlled pilot study.

Authors:  Hiroaki Naritomi; Hiroshi Moriwaki; Norifumi Metoki; Hiroyuki Nishimura; Yasuto Higashi; Yasumasa Yamamoto; Hiroyuki Yuasa; Hiroshi Oe; Kortaro Tanaka; Kozue Saito; Yasuo Terayama; Tadafumi Oda; Norio Tanahashi; Hisao Kondo
Journal:  Drugs R D       Date:  2010
View more
  46 in total

Review 1.  A review of neuroprotection pharmacology and therapies in patients with acute traumatic brain injury.

Authors:  Kevin W McConeghy; Jimmi Hatton; Lindsey Hughes; Aaron M Cook
Journal:  CNS Drugs       Date:  2012-07-01       Impact factor: 5.749

2.  Edaravone ameliorates oxidative stress associated cholinergic dysfunction and limits apoptotic response following focal cerebral ischemia in rat.

Authors:  Ajmal Ahmad; Mohd Moshahid Khan; Hayate Javed; Syed Shadab Raza; Tauheed Ishrat; M Badruzzaman Khan; Mohammed M Safhi; Fakhrul Islam
Journal:  Mol Cell Biochem       Date:  2012-05-22       Impact factor: 3.396

Review 3.  Factors controlling permeability of the blood-brain barrier.

Authors:  Mohammed M A Almutairi; Chen Gong; Yuexian G Xu; Yanzhong Chang; Honglian Shi
Journal:  Cell Mol Life Sci       Date:  2015-09-24       Impact factor: 9.261

4.  Apoptosis of Purkinje and granular cells of the cerebellum following chronic ethanol intake.

Authors:  Suelen A Oliveira; Luiz Gustavo A Chuffa; Beatriz Aparecida Fioruci-Fontanelli; Fermino Sanches Lizarte Neto; Paulo Cezar Novais; Luiz Fernando Tirapelli; Jorge Camargo Oishi; Luiz Fernando Takase; Maira Aparecida Stefanini; Marcelo Martinez; Francisco Eduardo Martinez
Journal:  Cerebellum       Date:  2014-12       Impact factor: 3.847

5.  Edaravone reduces astrogliosis and apoptosis in young rats with kaolin-induced hydrocephalus.

Authors:  Camila Araújo Bernardino Garcia; Carlos Henrique Rocha Catalão; Hélio Rubens Machado; Ivair Matias Júnior; Thais Helena Romeiro; José Eduardo Peixoto-Santos; Marcelo Volpon Santos; Luiza da Silva Lopes
Journal:  Childs Nerv Syst       Date:  2016-12-17       Impact factor: 1.475

6.  Inhibition of the integrated stress response reverses cognitive deficits after traumatic brain injury.

Authors:  Austin Chou; Karen Krukowski; Timothy Jopson; Ping Jun Zhu; Mauro Costa-Mattioli; Peter Walter; Susanna Rosi
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-10       Impact factor: 11.205

Review 7.  Oxidative stress, DNA damage, and the telomeric complex as therapeutic targets in acute neurodegeneration.

Authors:  Joshua A Smith; Sookyoung Park; James S Krause; Naren L Banik
Journal:  Neurochem Int       Date:  2013-02-17       Impact factor: 3.921

8.  Edaravone mitigates hexavalent chromium-induced oxidative stress and depletion of antioxidant enzymes while estrogen restores antioxidant enzymes in the rat ovary in F1 offspring.

Authors:  Jone A Stanley; Kirthiram K Sivakumar; Joe A Arosh; Robert C Burghardt; Sakhila K Banu
Journal:  Biol Reprod       Date:  2014-05-07       Impact factor: 4.285

9.  Quinolinic Acid-Induced Huntington Disease-Like Symptoms Mitigated by Potent Free Radical Scavenger Edaravone-a Pilot Study on Neurobehavioral, Biochemical, and Histological Approach in Male Wistar Rats.

Authors:  Thangarajan Sumathi; Aishwariya Vedagiri; Surekha Ramachandran; Bhagyalakshmi Purushothaman
Journal:  J Mol Neurosci       Date:  2018-10-03       Impact factor: 3.444

10.  Valproic acid protects motor neuron death by inhibiting oxidative stress and endoplasmic reticulum stress-mediated cytochrome C release after spinal cord injury.

Authors:  Jee Y Lee; Sejung Maeng; So R Kang; Hye Y Choi; Tae H Oh; Bong G Ju; Tae Y Yune
Journal:  J Neurotrauma       Date:  2014-01-23       Impact factor: 5.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.